Skip to main content

Fiona Kaper is a Vice President and Distinguished Scientist, Advanced Science at Illumina,, where she is responsible for all research and technology development of the next generation of Illumina assays and library prep methods that support research and clinical applications. She has contributed to many different products and innovations, including the VeriSeq PGS product lines (now Vitrolife), methods for the interrogation of circulating nucleic acids, and, most recently, the Illumina COVIDSeq Assay to identify and track strains of SARS-CoV-2.

Leave a Reply